• Director, LeRoy W Matthews, MD, Cystic Fibrosis Center, UH Rainbow Babies and Children's Hospital
  • Vice Chairman, Clinical Research, UH Rainbow Babies and Children's Hospital
  • Professor, Pediatrics, CWRU School of Medicine

(216)844-3267

Bio

Michael W. Konstan, MD, is the Chairman of the Department of Pediatrics at University Hospitals Case Medical Center and the Austin Ricci Chair in Pediatric Pulmonary Care and Research at UH Rainbow Babies & Children’s Hospital. He is also the Gertrude Lee Chandler Tucker Professor and Chairman of Pediatrics at Case Western Reserve University School of Medicine.

He is board certified in pediatrics and pediatric pulmonology. His special interest is cystic fibrosis.

Dr. Konstan is a graduate of Case Western Reserve University School of Medicine. He completed his residency in pediatrics at Children's Hospital of Buffalo in Buffalo, N.Y., and a fellowship in pediatric pulmonology at UH Rainbow Babies and Children’s Hospital and Case Western Reserve University School of Medicine. He was named to the University Hospitals medical staff in 1988.

Dr. Konstan has served on numerous advisory boards and grant review committees for the Cystic Fibrosis Foundation, the U.S. Food and Drug Administration (FDA), the National Institutes of Health, and many pharmaceutical and biotechnology companies. He was a founding member of the Cystic Fibrosis Foundation Therapeutic Development Network, and he currently serves on the Cystic Fibrosis Foundation Research Executive Committee. Locally, he serves on the Board of Directors of the foundation’s Northern Ohio Chapter.

An internationally renowned physician-scientist specializing in cystic fibrosis, Dr. Konstan’s research has been funded by the Cystic Fibrosis Foundation, the FDA, the National Institutes of Health, and numerous pharmaceutical and biotechnology companies focused on developing therapeutics for the treatment and cure of cystic fibrosis. He has been the lead investigator on several national and international clinical trials that have led to the approval of new therapeutics for cystic fibrosis.

Dr. Konstan has published more than 150 peer-reviewed papers in leading medical journals reporting basic and clinical research related to cystic fibrosis, as well as more than a dozen textbook chapters. He has presented more than 200 abstracts at scientific meetings and conferences, both nationally and internationally. He also is a reviewer for numerous peer-reviewed journals, including the Journal of the American Medical Association, Lancet, and the New England Journal of Medicine.

In 2013, Dr. Konstan was awarded the Case Western Reserve Medal for Excellence in Health Science Innovation by the School of Medicine. He is a member of the American Pediatric Society, American Academy of Pediatrics, American Thoracic Society, and Society for Pediatric Research.

Board Certifications

American Board of Pediatrics - Pediatric Pulmonology
American Board of Pediatrics - Pediatrics

Education & Training

Undergraduate

1978, Case Western Reserve University

Medical / Professional School(s)

1982, Case Western Reserve University School of Medicine

Internship

1983, Pediatrics - Kaleida Health System (Women and Children's Hosp of Buffalo)

Residency

1985, Pediatrics - Kaleida Health System (Women and Children's Hosp of Buffalo)

Fellowship

1988, Pediatric Pulmonology - University Hospitals of Cleveland

Expertise

Cystic Fibrosis

Awards & Recognition

Case Western Reserve Medal for Excellence in Health Science Innovation, School of Medicine, 2013
Best Doctors in America, 1998-2014
America’s Top Doctors, 2003 - 2014
Richard C. Talamo Distinguished Clinical Achievement Award, Cystic Fibrosis Foundation, 2009
“All Stars Among Us” Major League Baseball and People Magazine award for community service, 2009
Crain’s Cleveland Business “Health Care Heroes” finalist, 2009

Office Locations

UH Rainbow Babies and Children's Hospital
(216)844-3267
Department of Pediatrics-Pulmonary
11100 Euclid Ave
Cleveland, OH 44106
Get Directions

Research Interests

Cystic fibrosis

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

For calendar year 2013, Michael Konstan, MD disclosed the following Outside Relationships with Industry:


Aradigm - Consulting

Axcan-Pharma - Consulting

Eli Lilly - Consulting

Genentech - Consulting

Novartis - Consulting

Vertex - Consulting